(Yicai) Nov. 10 -- Shares of Sino Medical Sciences Technology rose after the Chinese medical devices supplier said the European Union Medical Devices Regulation has approved its latest drug-eluting stent for registration and marketing.
After jumping by as much as 6 percent earlier today, SinoMed [SHA: 688108] ended 3.2 percent higher at CNY13.48 (USD1.85) a share. The Shanghai market fell 0.5 percent.
The HT Supreme DES can improve vascular stenosis caused by primary coronary artery disease, the Tianjin-based company said late yesterday. Its design, which uses SinoMed's proprietary technology, makes it safer than traditional drug-eluting stents, it noted.
China approved the HT Supreme DES in December 2020 and listed it in the national medical insurance catalog last November. The stent is also available in Thailand, Singapore, Indonesia, Türkiye, and China's Taiwan, according to SinoMed.
Editor: Martin Kadiev